Enabling Better and Faster Treatment for Patients
with Hematologic Malignancies.
HARMONY Alliance to attend 2nd European Myeloma Network meeting
HARMONY Alliance session at the European Leukemia Net Meeting
HARMONY Co-Lead, Celgene
"HARMONY will to allow us to understand the outcomes that matter to patients and through the big data platform, identify targets, risk factors or treatments which will accelerate access of
Ransohoff, VP, Global External Innovation, Bayer
"The HARMONY consortium is committed to enabling the use of high-quality clinical and genomic data for the benefit of patients with Hematological Malignancies. Our consortium provides a solid and ...
HARMONY Communication Manager, European Hematology Association
"We will make a difference by communicating about real developments and achievements which are realized by the teams of the HARMONY Work Packages, HM Disease Groups and Research Projects. Through ...
Oncology communications consultant, Novartis
"The HARMONY Alliance is the result of outstanding public-private collaborations through the exchange of information, the sharing of knowledge and open communications among all stakeholders. It
Managing Director, European Hematology Association (EHA)
"The collaboration and firm commitment of industry, HTA, payers and other stakeholder experts plus the input of patients is key to the HARMONY Alliance. Harmonising hematology and big data will
Newcastle University, HARMONY Key Opinion Leaders for Childhood Leukemia
"Sharing data is crucial to further research in Hematological Malignancies because many of these cancers are heterogeneous in terms of their genetic profile. Many genetic profiles are rare;
Director, Oncology1/WHC, Bayer
"Looking forward to working together with so many public and private partners on defining outcomes sets for HMs which include both clinical outcome measures and patient factors for patients and caregivers.The ...
Professor in Personalized Medicine, Charité
"Hematological malignancies (HMs) are a role model for the treatment of many cancers. Being characterized by a tremendous heterogeneity, HMs are hard to come by with “one size fits all” ...
Director Data Sciences, JPNV-JANSSEN
"Public and private partners are bringing together their best people, data, and knowledge to solve key questions on hematological cancers. These challenges can only be met by applying the most advanced ...
Project Coordinator, GMV Soluciones Globales Internet (GMV)
"The Big Data platform, to be developed in WP3, will support data homogenization on a common data model to create relationships and allow advance analysis and studies between treatments, health
Professor Department of Physics and Astronomy Academic discipline. Alma Mater Studiorum - Università di Bologna
"WP5 aims to develop methodologies for statistical analysis and modelling of both molecular and clinical data coming from patients with hematological malignancies, identifying possible specific disease ...